Summary

For symptomatic therapy, the expected outcome is symptom control; guidelines state that treatment goals are to reduce symptom burden, maximize function, and optimize quality of life. For a disease-modifying therapy such as SKY-0515, the expected outcome is slower clinical progression, measured in current trials by change in the cUHDRS, a composite of TFC, TMS, SDMT, and Stroop Word Reading, and by its TFC component. An anchor-based analysis of registry data proposed a cUHDRS decline of 1.2 points as a clinically meaningful within-patient change. The sponsor of AMT-130 reported in 2025 that the FDA considered the cUHDRS an acceptable intermediate clinical endpoint for accelerated approval, and the phase 3 INVEST-HD trial of votoplam uses change in cUHDRS to month 36 as its primary endpoint. Other endpoints proposed for earlier-stage populations include time to HD-ISS stage 3 (functional decline); modeling of a 9-month or longer delay in that transition yielded feasible sample sizes. Decision modeling indicates that the health effects of a disease-modifying therapy depend on stage at treatment: a hypothetical therapy produced life-year and QALY gains in all modeled populations, and cost savings only in individuals treated before functional decline.

Composite clinical progression measure in early Huntington's disease

“Use of a composite motor, cognitive, and global functional clinical outcome measure in HD provides an improved measure of clinical progression more related to measures of progressive brain atrophy and provides an opportunity for enhanced clinical trial efficiency relative to currently used individual motor, cognitive, and functional outcome measures.” (opens the source at this quote in a new tab)

Clinically meaningful change on the cUHDRS

“Analyses anchored against CGI-S and IS support that a decline on the cUHDRS of 1.2 points is clinically meaningful, and that the cUHDRS tracks function decline.” (opens the source at this quote in a new tab)
“Based on these values, a decline of 1.2 points is recommended as an estimate of meaningful within-patient decline for use in a responder analysis endpoint in clinical trials in patients with early manifest HD.” (opens the source at this quote in a new tab)

Regulatory acceptance of cUHDRS as an intermediate clinical endpoint: sponsor-reported FDA feedback

“The FDA continued to support its prior agreement that the composite Unified Huntington’s Disease Rating Scale (cUHDRS) may serve as an acceptable registrational, intermediate clinical endpoint for accelerated approval.” (opens the source at this quote in a new tab)

Phase 3 disease-modifying trial endpoint: votoplam INVEST-HD

“The primary endpoint will be the change from baseline up to month 36 in the cUHDRS.” (opens the source at this quote in a new tab)

SKY-0515 trial outcome measures

“Primary outcome measures are change from baseline to 12 months in blood mHTT protein levels, MRI-derived brain volumes and UHDRS scores.” (opens the source at this quote in a new tab)

Time to functional decline as an endpoint

“A delay of 9 months or more in the transition to Stage 3 for an enriched sample yields feasible sample size estimates, demonstrating that this approach can aid in planning future trials.” (opens the source at this quote in a new tab)

Cognitive endpoints and regulatory meaningfulness

“Thus, improvements or declines in performance on the SDMT alone are not sufficient for demonstrating meaningful effects that could lead to regulatory approval of a treatment.” (opens the source at this quote in a new tab)

Aims of disease-modifying treatment and modeled long-term outcomes

“Potential disease-modifying treatments (DMTs) such as gene therapy (GTx), antisense oligonucleotides (ASOs), and small molecule–based therapeutic approaches aim to provide long-term health benefits for people with HD by slowing down, arresting, or even reverting disease progression.” (opens the source at this quote in a new tab)
“Although hypothetical DMTs led to cost savings in the PFD population by delaying the cost burdens of functional decline, they increased costs in SF1 and SF2 populations by prolonging time spent in expensive progressive HD states.” (opens the source at this quote in a new tab)

Expected outcomes of symptomatic chorea treatment

“By integrating pharmacologic therapy with multidisciplinary care and holistic, goal-oriented communication about the impact of chorea, clinicians can meaningfully improve safety, independence, and quality of life for individuals and families affected by HD.” (opens the source at this quote in a new tab)